VANCOUVER, British Columbia (AP) _ Novelion Therapeutics Inc. (NVLN) on Tuesday reported a loss of $31.8 million in its first quarter.
The Vancouver, British Columbia-based company said it had a loss of $1.67 per share. Earnings, adjusted for non-recurring costs and stock option expense, were 10 cents per share.
The retinal disease treatment developer posted revenue of $32.2 million in the period.
Novelion Therapeutics expects full-year revenue in the range of $160 million to $175 million.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVLN at https://www.zacks.com/ap/NVLN